Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels

Hypertension

Volumn 56, Issue 4, 2010, Pages 675-681

  Kappers, Mariëtte H W ^a   Van Esch, Joep H M ^a   Sluiter, Wim ^a   Sleijfer, Stefan ^a   Danser, A H Jan ^a   Van Den Meiracker, Anton H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

angiogenesis; endothelial growth factors; endothelin; experimental; hypertension; NO

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; NITROPRUSSIDE SODIUM; PROTEIN TYROSINE KINASE INHIBITOR; RENIN; SUNITINIB;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEART RATE; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY FUNCTION; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AGED; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; BRADYKININ; CARCINOMA, RENAL CELL; CELLS, CULTURED; CORONARY CIRCULATION; ENDOTHELIAL CELLS; ENDOTHELIN-1; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HEART; HEART RATE; HUMANS; HYPERTENSION; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; RATS; RATS, INBRED WKY; RECEPTOR PROTEIN-TYROSINE KINASES; RENIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77957231200     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.149690     Document Type: Article

References (27)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
2. Kappers MH, van Esch JH, Sleijfer S, Danser AH, van den Meiracker AH. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. J Hypertens. 2009;27:2297-2309.
3. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788-1795. (Pubitemid 46912024)
4. Hovens MMC, Steeghs N, Gelderblom H, Op t Roodt J, Matthys A, Christensen O, Rabelink AJ. VEGFR2 blockade in patients with solid tumors: Mechanism of hypertension and effects on vascular function. Vascul Pharmacol. 2006;45:e42-e43.
5. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011-2019. (Pubitemid 350236338)
6. Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, Hynes J, Patyna S, Jessen BA. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and h9c2 cells. Toxicol Sci. 2008;106:153-161.
7. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens. 2005;23:417-426. (Pubitemid 40279646)
8. van Esch JHM, Oosterveer CR, Batenburg WW, van Veghel R, Danser AHJ. Effects of angiotensin II and its metabolites in the rat coronary vascular bed: Is angiotensin III the preferred ligand of the angiotensin AT(2) receptor? Eur J Pharmacol. 2008;588:286-293.
9. McFalls EO, Sluiter W, Schoonderwoerd K, Manintveld OC, Lamers JM, Bezstarosti K, van Beusekom HM, Sikora J, Ward HB, Merkus D, Duncker DJ. Mitochondrial adaptations within chronically ischemic swine myocardium. J Mol Cell Cardiol. 2006;41:980-988. (Pubitemid 44791328)
10. van Kerckhoven R, Saxena PR, Schoemaker RG. Restored capillary density in spared myocardium of infarcted rats improves ischemic tolerance. J Cardiovasc Pharmacol. 2002;40:370-380. (Pubitemid 34971354)
11. van den Eijnden MM, Saris JJ, de Bruin RJ, de Wit E, Sluiter W, Reudelhuber TL, Schalekamp MA, Derkx FH, Danser AH. Prorenin accumulation and activation in human endothelial cells: Importance of mannose 6-phosphate receptors. Arterioscler Thromb Vasc Biol. 2001; 21:911-916. (Pubitemid 34168645)
12. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. In vivo antitumor activity of su11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327-337. (Pubitemid 36109749)
13. Derkx FH, Steunkel C, Schalekamp MP, Visser W, Huisveld IH, Schalekamp MA. Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in women taking oral contraceptives. J Clin Endocrinol Metab. 1986;63:1008-1015.
14. Alberts G, Boomsma F, Man in t Veld AJ, Schalekamp MA. Simultaneous determination of catecholamines and dobutamine in human plasma and urine by high-performance liquid chromatography with fluorimetric detection. J Chromatogr. 1992;583:236-240.
15. Boomsma F, Alberts G, van Eijk L, Manin't Veld AJ, Schalekamp MA. Optimal collection and storage conditions for catecholamine measurements in human plasma and urine. Clin Chem. 1993;39:2503-2508. (Pubitemid 24008237)
16. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med. 2008;358:95-97.
17. Banfor PN, Franklin PA, Segreti JA, Widomski DL, Davidsen SK, Albert DH, Cox BF, Fryer RM, Gintant GA. ETa receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats. J Cardiovasc Pharmacol. 2009;53:173-178.
18. Naiker S, Naidoo S, Naicker T, Gathiram P, Nadar A, Moodley J. Immunolocalisation and endothelin-1 values in pre-eclampsia: an immunocytochemical study. J Obstet Gynaecol. 2001;21:39-45. (Pubitemid 32154453)
19. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683. (Pubitemid 38364626)
20. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sflt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658. (Pubitemid 36278583)
21. Murphy SR, LaMarca BB, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension. 2010;55:394-398.
22. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, ODwyer PJ. Mechanisms of hypertension associated with bay 43-9006. J Clin Oncol. 2006;24:1363-1369. (Pubitemid 46621999)
23. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129-1136. (Pubitemid 351398487)
24. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis. 2007;50:203-218. (Pubitemid 47095077)
25. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis. 2007;49:186-193. (Pubitemid 46178407)
26. Curwen JO, Musgrove HL, Kendrew J, Richmond GH, Ogilvie DJ, Wedge SR. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: Examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin Cancer Res. 2008;14:3124-3131.
27. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7:332-344. (Pubitemid 46652481)